Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | Zendy

Talia Golan | Zendy; Pascal Hammel | Zendy; Michele Reni | Zendy; Eric Van Cutsem | Zendy; Teresa Macarulla | Zendy; Michael J. Hall | Zendy; Joon-Oh Park | Zendy; Daniel Hochhauser | Zendy; Dirk Arnold | Zendy; DoYoun Oh | Zendy; Anke ReinacherSchick | Zendy; Giampaolo Tortora | Zendy; Hana Algül | Zendy; Eileen M. O’Reilly | Zendy; David McGuinness | Zendy; Karen Cui | Zendy; Katia Schlienger | Zendy; Gershon Y. Locker | Zendy; Hedy L. Kindler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Author(s) -

Talia Golan,

Pascal Hammel,

Michele Reni,

Eric Van Cutsem,

Teresa Macarulla,

Michael J. Hall,

Joon-Oh Park,

Daniel Hochhauser,

Dirk Arnold,

DoYoun Oh,

Anke ReinacherSchick,

Giampaolo Tortora,

Hana Algül,

Eileen M. O’Reilly,

David McGuinness,

Karen Cui,

Katia Schlienger,

Gershon Y. Locker,

Hedy L. Kindler

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903387

Subject(s) - olaparib , germline , parp inhibitor , polymerase , poly adp ribose polymerase , cancer research , pancreatic cancer , germline mutation , medicine , mutation , oncology , cancer , biology , genetics , dna , gene

Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research